Checkpoint inhibitors such as nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4) that prevent PD-1/PD-L1, PD-1/PD-L2, and CTLA4/B7 interactions are now FDA approved for treating a wide range of cancers [3]. This evidence concerns the gene CTLA4 and cancer.